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1. Introduction
Chronic obstructive pulmonary disease (COPD) is a disease which is characterized by airway
inflammation and progressive airflow limitation with poor reversibility. Patients with COPD
can experience periods of acute deterioration, which are called exacerbations. There are
different definitions for an acute exacerbation of COPD (AECOPD). A symptom reported
AECOPD is defined solely based on a patient’s symptoms [1]. This is regardless of whether
the patient seeks medical attention or receives treatment for the exacerbation. An event defined
AECOPD requires a therapeutic intervention such as a change in COPD medications or a
change in healthcare utilization [1]. Generally accepted is the definition as in the guidelines of
the World Health Organization, US National Heart Lung and Blood Institute and Global
Initiative for Chronic Obstructive Lung Disease (GOLD), which define an exacerbation as “an
event in the natural course of the disease characterized by a change in the patient’s baseline
dyspnoea, cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset
and may warrant a change in regular medication in a patient with COPD” [2]. Frequent
exacerbations can result in a decreased health related quality of life [3], a decline in lung
function [4], an increased risk of hospitalization [5] and an increase in mortality [6].
COPD and acute exacerbations of COPD (AECOPD) impose a burden on health care and so‐
ciety. It is estimated that COPD is the 4th leading cause of death worldwide and will be the
3rd leading cause of death in 2030 [7]. Along with increasing mortality rates, the loss in disa‐
bility-adjusted life years (DALYs) also rises. By 2030 COPD will be the 5th leading cause of
loss in DALYs globally, where it was only number 13 in 2004. Increasing health care costs
will be the consequence of this trend. In the European Union COPD accounts for just over
3% of the total health care budget. In the USA, the direct and indirect costs for COPD are
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almost 50 billion USD. The majority of these costs are attributed to exacerbations [8]. The im‐
portance of exacerbations is reflected in the latest update of the GOLD report, in which the
number of exacerbations in the preceding year is incorporated in the new classification of a
patient with COPD [8]. In order to try to reduce the mortality, loss in DALYs and related
costs and to lower the burden on society and health care, it is a goal to prevent and treat
COPD and exacerbations of COPD. This chapter will give a concise overview of the back‐
ground of AECOPD and the available tools for its treatment and prevention.
2. Epidemiology
The prevalence of COPD varies greatly per country and also within countries [9]. This
heterogeneity can be contributed to not only differences in diagnostic methods and classifica‐
tion but also to smoking habits, population age, in- and outdoor air pollution, occupational
exposure, prevalence of pulmonary tuberculosis, chronic asthma and socioeconomic status
[10]. Prevalences of COPD have been reported varying from 0,2-37% [11, 12]. The prevalence
of AECOPD is very difficult to determine since there is no generally agreed definition for an
AECOPD (see above). Studies show that only 32-50% of symptom defined AECOPD are
reported by patients to health care professionals [13, 14]. Although there is no reliable estimate
of the prevalence of AECOPD, much is known about the occurrence of exacerbations. Research
shows that exacerbations are more frequent in the winter season [15] and may occur clustered
in time [16]. Exacerbations are also more frequent and severe as COPD severity increases [17].
Besides COPD severity, the history of exacerbations is also a good predictor of future exacer‐
bations [17]. Furthermore, there is a strong correlation with symptoms of depression and
recurrent exacerbations [18, 19].
3. Pathophysiology of COPD and AECOPD
COPD is the result of a chronic inflammation in the airways. The inflammation is initiated by
chronic exposure to exogenic toxins (e.g. cigarette smoke) which is causing damage to the
airway epithelium and is activating the innate immune system giving a rapid, nonspecific
response [20, 21]. Of the innate immune response the neutrophillic inflammation is most
prominent in COPD. The cells of the innate immune system activate the adaptive immune
system, of which CD8+-cells, CD4+ Thelper1 cells and B-cells have an important role in COPD.
This activation of the adaptive immune response is the beginning of a cascade which causes
extensive chronic inflammation, oxidative stress and remodeling, resulting in destruction of
alveolar space and deposition of connective tissue in the subepithelium and adventitium of
the airway wall [22]. The degree of chronic inflammation in COPD correlates with the severity
of airflow limitation. This is supported by a correlation which is seen between the severity of
obstruction and presence of CD8+-cells and B-cells in the small conducting airways [22] and
the presence of neutrophils in sputum [23]. Also, bacterial colonization is more frequently
observed in patients with severe to very severe COPD, suggesting that bacterial colonization
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induces inflammation and contributes to the progression of COPD [24, 25]. The existence of
the chronic inflammation and oxidative stress is supported by the presence of oxidants and
numerous pro-inflammatory cytokines in the airways and serum. Compared to healthy
controls, sputum specimens of patients with stable COPD and AECOPD show increased
numbers of neutrophils and increased levels of pro-inflammatory cytokines like interleukin-6
(IL-6) and interleukin-8 (IL-8) [21, 23, 26-29]. During an AECOPD neutrophils, IL-6 and IL-8
are also increased in serum [27, 30, 31]. Interleukin-6 is a cytokine released during initial
immune response by different cell types of the native immune system, like macrophages. It
induces hepatic acute phase response during inflammation [32] which in turn increases
production of C-reactive protein (CRP). Interleukin-6 is also a growth factor for T- and B-cells
[33]. Interleuking-8 is released by a variety of cell types involved in inflammation, like
endothelial cells, fibroblasts and monocytes [34]. It is a potent neutrophil chemotactic and
activating factor [34]. The presence of the increased inflammation in serum both during stable
state and AECOPD may be explained by the “overspill theory”, in which the local inflamma‐
tory processes in the lung “spill over” to the systemic circulation [35]. It is therefore thought
that disease activity of COPD can be measured in serum by biomarkers. Exhaled breath
condensate (EBC) components are thought to reflect the physiological state of lining fluid of
the airways. It’s a non-invasive mean of obtaining information on oxidative stress and
inflammation in the airways. Hydrogen peroxide (H2O2, a precursor of potent oxidants OH
and HOCl) and 8-isoprostane (formed by the free radical peroxidation of arachidonic acid) are
EBC oxidative stress biomarkers proven to be elevated in patients with COPD during stable
state and during exacerbations [31, 36-38]. Heme-oxygenase-1 (HO-1) is an inducible catalyzer
of the degradation of heme to biliverdin which is thought to provide protection from oxidative
stress. It is decreased in ex-smokers with COPD compared to control subjects [39] but increased
during severe exacerbations [29], in healthy smokers and current smokers with COPD [40].
4. Aetiology of AECOPD
4.1. Microbiology
There is a great variety in reported infectious causes of COPD exacerbations. It is of importance
to determine, both for bacteria and viruses, whether the presence of the microbe is actually the
cause of the exacerbation. Estimated is that about 50-78% of acute exacerbations of COPD are
caused by respiratory infections [24, 27, 41, 42], in which the clinical presentation range from
pneumonia to coryzal symptoms with dyspnea. Patients with AECOPD of proven infectious
aetiology have a longer hospital stay and a greater decrease in FEV1 than patients with non-
infective exacerbations [27].
4.2. Viral causes
In the past viruses have been an underestimated cause of AECOPD and the causative role of
viruses in AECOPD is still not fully established. The observation that as well viral infections
and exacerbations are seasonal does suggest that viruses have a role in AECOPD [15, 43].
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Recently researchers deliberately exposed patients with COPD and healthy smokers to
rhinoviruses and observed that this virus was able to cause an exacerbation in patients with
COPD [44]. Detection of viruses by culture and by serology, where a second serum sample is
also required, is less sensitive and more time consuming than PCR techniques, where only 1
sample is required. Because of the advanced PCR techniques in detecting viruses, the per‐
centage of exacerbations they account for can also be overestimated. The presence of viral DNA
or RNA does not implicate that the virus is the cause of an exacerbation as several studies
reported patients with stable COPD to carry viruses with percentages varying from 12-19%
[45, 46]. In exacerbations several studies have reported that viruses were detected in 20-56%
of cases [24, 27, 41, 42, 46, 47]. In these studies rhinovirus, influenza virus and respiratory
syncytial virus and were the most common isolated viruses. A more extensive overview can
be found in table 1.
COPD exacerbations: divided by cause
Bacteria
Streptococcus pneumoniae
Haemophilus influenzae
Moraxella catarrhalis
Haemophilus parainfluenzae
Pseudomonas aeruginosa
Staphylococcus aureus
Viruses
Human rhinovirus
Respiratory syncytial virus
Influenza virus
Parainfluenza virus
Human metapneuvirus
Coronavirus
Adenovirus
Atypical microorganisms
Mycoplasma pneumoniae
Chlamydophila pneumoniae
Legionella pneumophila
Coxiella burnetii
Other
Sulphur dioxide (SO2)
Ozone (O3)
Nitrogen dioxide (NO2)
Particulate matter (PM2,5 , PM10)
Table 1. Most common causes of exacerbations of COPD.
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4.3. Bacterial causes
Bacteria as cause of AECOPD are reported from 30% [48] up to 55% [27, 49]. The most common
bacterial pathogens are Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
and in patients with more severe COPD also Pseudomonas aeruginosa [42, 48]. It is difficult to
determine the role of bacteria in AECOPD, as 34-48% of patients with COPD are reported to
be colonized with bacteria [26, 27, 50, 51]. Molecular typing of bacteria during exacerbations
showed that the acquisition of new strains may cause exacerbations [52], but not every
acquisition of a new strain is linked to an exacerbation.
4.4. Non-microbial causes
One tenth of AECOPD are due to environmental pollution, of which ozone, sulphur dioxide
and nitrogen dioxide known and researched causes [53, 54]. Particulate matter (PM) is also
related to increased admissions for COPD and other respiratory diseases [53, 55]. Particulate
matter consists of a mixture of solid particles and liquid aerosols suspended in the air from
natural sources, industrial activities and can also be traffic related [56]. Other possible, non-
infectious causes may be left sided heart failure, change in environmental temperature, but
about 30% of exacerbations are of unknown origin [6].
5. Clinical Presentation and Diagnosis
5.1. History
Patients with an AECOPD usually present with dyspnea, which may be acute but can also be
a history of slowly progressive dyspnea. Coughing or sputum production may or may not be
present. When expectorating sputum, it is important to assess whether sputum volume has
increased and whether it is purulent (e.g. green). Purulent sputum is usually a sign of infection
[57]. Fever or other signs of infection should be looked for. Hemoptysis may be present in case
of a severe infection. Risk factors for atypical infections should be thought of.
5.2. Laboratory tests
Laboratory test can be performed if necessary. C-reactive protein as marker for inflamma‐
tion can be  performed.  Additional  laboratory tests  can be  performed depending on the
differential diagnosis. If available, an arterial blood gas can be performed. Hypoxemia may
be present and in more severe cases a patient can also retain CO2. Hypercapnia is defined
as  arterial  blood  gas  CO2  (PaCO2)  level  above  45  mmHg  (6,00  kPa)  and  hypercapnic
respiratory failure as PaCO2 of >50 mmHg (6,67 kPa). When present it is important to assess
if the hypercapnia is longer existing and to assess if the patient is being able to metabolical‐
ly compensate the hypercapnia.
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5.3. Radiology
A chest X-ray is mainly useful for excluding other pathology like pneumothorax, pleural fluid,
congestive heart failure or otherwise. It may reveal consolidations or other pathology. In the
acute phase a chest CT-scan has no additive value in the tract of diagnosing an exacerbation
of COPD. It can be performed if doubts exist about the presence of pulmonary embolisms as
an explanation for dyspnea and/or desaturation. In a patient with recurrent airways infections
a CT-thorax can be performed to investigate whether bronchiectasis is present.
5.4. Biomarkers
Biomarkers can be used as indicators of a physiological state in which a patient is or may
become, it can help in diagnosis, aetiology and prognosis. In theory, biomarkers could be used
to predict exacerbations, to determine if a patient has increased inflammation, to distinguish
type of inflammation (bacterial or viral infection or otherwise) or to predict clinical outcome
after an AECOPD.
Many biomarkers have been researched of which many of them are of little clinical use. At this
moment the most important biomarkers in AECOPD are CRP, serum IL-6, 8-isoprostane,
H2O2 and procalcitonin (ProCT). These biomarkers are closely related to oxidative stress and
inflammation. C-reactive protein is momentarily the most widely used marker of inflammation
in clinical practice.
In patients with frequent exacerbations, both CRP and serum IL-6 levels are increased during
a stable phase but also during the recovery period of an AECOPD [58, 59] compared to patients
with infrequent exacerbations. Interleukin-6 is a cytokine which is widely expressed and
produced in the body, and is not specific to the lung. Serum IL-6 has no additional value above
CRP in clinical decision making. Interleukin-6 levels in sputum may be of use to predict therapy
response [58], although more research is needed before clinical decisions can be made based
on this biomarker. Similarly, there is a lack of studies which investigate the use of exhaled
biomarkers 8-isoporstane and H2O2 for clinical purposes. Procalcitonin may be a biomarker
which can discriminate in aetiology of an exacerbation but may also be used as therapeutic
response parameter. Procalcitonin is the precursor of calcitonin and is released in response to
a bacterial infection by many tissues under stimulation of several cytokines. Procalcitonin
levels are minimally raised in viral infections [60], making it a relative specific diagnostic tool
for bacterial infections. Most research has been performed in patients with community
acquired pneumonia (CAP) [61]. It is suggested that ProCT could become a useful tool in
clinical decision making regarding antibiotic therapy. There have been several trials to assess
the utility of ProCT in AECOPD. In general ProCT-guided antibiotic therapy compared to
standard management in AECOPD showed no differences in death from any cause, rates of
intensive care unit (ICU) admission for any reason, duration of ICU stay, improvement of
symptoms, difference in the quality-of-life score, re-exacerbation and readmission [62].
Procalcitonin-guided antibiotic therapy showed reduction in antibiotic prescription [62] and
in one study [63] also reduction in antibiotic therapy duration, which in turn decreases the
patient’s exposure to antibiotics and related side effects, lowers the burden of antibiotic use
and the risk of antimicrobial resistance. Procalcitonin is not yet being implemented in standard
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care though, as it is relatively expensive and there has been little to no research performed
outside Europe.
6. Management
The treatment of an AECOPD consists of supportive therapy, maximal bronchodilation,
steroids to reduce the inflammation and treatment of the cause.
6.1. Supportive therapy
Oxygen delivery is one of the first supportive therapies which can be provided for a patient.
Oxygen saturation should be at least 90% though in some cases lower saturations may also be
accepted. Too much oxygen may cause hypercapnia as the drive to breathe in some COPD
patients may rely on arterial O2 pressure. Symptoms of acute hypercapnia are somnolence,
headache, drowsiness, confusion, flushed skin or agitation. Physiotherapy during an admis‐
sion for an AECOPD can prevent deterioration in skeletal muscle function and improve
exercise capacity [64, 65]. Because an AECOPD is accompanied by an impaired energy balance
due to a decreased dietary intake and an increased resting energy expenditure, nutritional
support may also benefit the patient in terms of general well-being and prevention of muscle
wasting [66-68].
6.2. Pharmacotherapy
An exacerbation is the result of increased inflammation causing increased flow limitation.
Treatment should be directed towards controlling this exacerbated inflammation and maxi‐
mizing bronchodilation. Short acting agents like salbutamol and ipratropium are mostly used
for maximal bronchodilation, usually delivered by nebulizer. Many patients may not be able
to generate the flows required to use other devices during an exacerbation. Corticosteroids
have been proven to reduce time to recovery and treatment failure, increase FEV1 and arterial
hypoxemia [8]. Treatment schemes have been reported varying from 30 mg prednisolone
orally to 60 mg intravenous, ranging from 5 days to two weeks. Studies showed that there is
no difference in clinical outcome if a patient is treated with oral steroids compared to parenteral
steroids [69]. Antibiotic treatment can be initiated when a bacterial infection is suspected. With
the Anthonisen criteria [70] one can decide whether antibiotic treatment is necessary or not.
These criteria are derived from a randomized placebo-controlled crossover trial which has
been performed in the ‘80s where patients with COPD exacerbations were treated with
antibiotics or placebo. The cardinal symptoms of infection in this study were increased sputum
volume and purulence in combination with increased dyspnea. An exacerbation with all the
previous 3 symptoms is called a type 1 exacerbation; two out of three symptoms have to be
present for a type 2 exacerbation; one out of three and at least one other “minor symptom”
(see table 2) have to be present for it to be a type 3 exacerbation. Patients with type 1 and type
2 exacerbations are most likely to benefit from antibiotic therapy. In Spain a pilot study was
performed with hospitalized patients with AECOPD, where antibiotic therapy was given to
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patients with self-reported purulent sputum and withheld in patients with non-purulent
sputum [71]. There was no difference between the two groups in treatment failure on day 3,
suggesting patient reported non-purulent sputum may be a valid criterion to withhold
antibiotics [71]. A Dutch study showed that addition of doxycycline to the treatment regimen
with glucocorticoids of a patient with an exacerbation was superior on day 10 but equivalent
on day 30 in terms of clinical success and clinical cure compared to glucocorticoids alone, even
in patients not showing signs of infection [72]. Most recently Spanish investigators performed
a multicenter trial where they suggested that treatment of a mild to moderate exacerbation
with amoxicillin/clavulanate, independent of glucocorticoids treatment, might give better
clinical cure after 10 days compared to placebo [73]. In this study the median time to next
exacerbation was also increased in patients receiving antibiotics compared to placebo.
Unfortunately, because of recruitment problems this study did not reach the calculated amount
of patients needed, so that definite conclusions cannot be made from the results of this study.
Classification of AECOPD according to
Anthonisen criteria
Presence of symptoms and findings
Type 1 Increased dyspnea
Increased sputum volume
Increased sputum purulence
Type 2 Two symptoms of type 1
Type 3 1 of three symptoms of type 1, plus at least one of the following
findings:
- Upper respiratory infection (sore throat, nasal discharge) within the
past 5 days
- Fever without other cause
- Increased wheezing
- Increased cough
- Increase in respiratory rate or heart rate by 20% as compared with
baseline
Table 2. Classification of acute exacerbations of COPD according to Anthonisen criteria [70]
7. Prevention
Preventing exacerbations is an important treatment goal in COPD. There is a wide range of
preventive measures which have proven to reduce exacerbation frequency or hospitalization
in patients with AECOPD.
7.1. Supportive measures
Influenza vaccination and pneumococcal vaccination have both been researched as preventive
measures for infection associated exacerbations. Current GOLD guidelines [8] advise influenza
vaccination for patients with COPD. Pneumococcal vaccination is mainly advised for elderly
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patients with COPD. Investigation on this subject is ongoing. Of the non-pharmacologic
interventions, pulmonary rehabilitation is the most effective in reducing hospital admissions
and mortality and improving health-related quality of life in COPD patients who have recently
suffered an exacerbation of COPD [74].
7.2. Long-acting bronchodilators
Long-acting bronchodilators can be divided in two groups: long acting muscarinic receptor
antagonists (LAMAs) and long acting β-agonists (LABAs). Both have proven to show a positive
effect on exacerbation reduction and improvement in quality of life [75-79]. An overview of
the long-acting bronchodilators is given in table 3.
LABA LAMA
Formoterol Tiotropium
Arfomoterol Glycopyrronium
Salmeterol
Indacaterol
Table 3. An overview of available long-acting bronchodilators.
Of the long-acting bronchodilators, indacaterol and glycopyrronium are the most recent
additions for the treatment of COPD. Indacaterol is proven to be superior to formoterol,
salmeterol and tiotropium in terms of use of rescue medication, dyspnoea score and health
related quality of life. Compared to salmeterol and formoterol it is also superior in improving
spirometry values. Indacaterol is non-inferior to tiotropium but when added to tiotropium
therapy it is superior compared to tiotropium alone [80]. Indacaterol also lowers the risk of
AECOPD compared to placebo [78, 81, 82]. Glycopyrronium has been approved in 2012 as
therapy for COPD. It provides significant improvements in lung function, dyspnoea, health
status, exacerbation frequency and rescue medication use versus placebo, and is comparable
to tiotropium [83, 84]. The combination of glycopyrronium and indacaterol has shown
superiority in bronchodilation compared to indacaterol alone [85]. Glycopyrronium has not
been compared to other LABAs yet.
7.3. Inhalation corticosteroids
Inhalation corticosteroids (ICS) can be given to patients with high risk of exacerbations. In
several studies ICS provided a reduction of symptoms (dyspnea, cough) and reduced the
frequency of exacerbations [86-88]. The GOLD guidelines advise treatment for high exacerba‐
tion risk patients with few symptoms (group C) with a combination of ICS/LABA or a LAMA
alone, or a combination of LABA and LAMA [8]. For high exacerbation risk patients who have
many symptoms (group D) the same treatment is advised as for group C, also a combination
of all three classes of inhalation drugs is possible [8].
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7.4. Phosphodiesterase inhibitors
Currently, two phosphodiesterase inhibitors are available for the treatment of COPD: theo‐
phylline and roflumilast. Theophylline is a xanthine derivative which acts as a non-selective
phosphodiesterase inhibitor. It has bronchodilator effects, improves symptoms and there is
evidence that it can reduce exacerbations [89-91]. It is a drug which needs therapeutic window
monitoring. It can interact with many drugs and can have toxic side effects which may be
potentially dangerous, like cardiac arrhythmia. Therapy with theophyllines is not recom‐
mended if LABAs are available but can be used as add-on therapy [8]. Roflumilast is a selective
phosphodiesterase-4 inhibitor. It increases prebronchodilator FEV1 and can reduce exacerba‐
tions in a selected group of patients with COPD [92, 93]. In all trials patients in the roflumilast
group experienced more side effects in comparison to patients in the placebo groups. The side
effects were mostly gastro-intestinal related (nausea, diarrhoea, weight loss) and headache.
These adverse events were associated with increased patient withdrawal in the roflumilast
groups. The design of the trials limits the generalizability of these results. The included COPD
patients were required to have symptoms of chronic bronchitis and AECOPD in the past. More
investigation is needed to determine the exact place of this medication in the treatment of
AECOPD.
7.5. Macrolide antibiotics
Antibiotic prevention of exacerbations is a highly researched topic in COPD. The most
promising class of antibiotics appear to be macrolides. In various chronic lung diseases they
seem to have an immune modulatory function.
7.5.1. Proposed working mechanism
Much in vivo and in vitro research has been performed with macrolide antibiotics. The effects
of macrolides can be divided in antimicrobial effects and immune modulatory effects.
Macrolides bind to the 50S subunit of the bacterial ribosome and inhibit bacterial protein
synthesis [94]. Most macrolides have a uniform degree of activity; their antimicrobial spectrum
extends from Gram-positive bacteria to a limited activity against Gram-negative bacteria [95].
Of the macrolides, azithromycin displays superior activity against Gram-negative organisms,
such as H. influenzae [94]. Compared to other macrolides as erythromycin and clarithromycin,
azithromycin also has better uptake in peripheral blood polymorphonuclear neutrophils
(PMN) with slower release [96, 97], better tissue uptake and tissue concentrations are higher
long after the last administered dose [98, 99]. Pseudomonas aeruginosa is a Gram-negative rod
which has intrinsic resistance for macrolides but has nonetheless been extensively studied in
combination with macrolides. Studies have shown that macrolides influence the virulence of
not only P. aeruginosa [100-102] but also other microorganisms, like Proteus mirabilis [103],
Salmonella enterica [104], Staphylococcus epidermidis [105] and H. influenzae [106]. Macrolides alter
the biofilm around bacteria [105-107], in P. aeruginosa this may facilitate phagocytosis by PMN
[101]. It is also suggested that macrolides block quorum sensing [108, 109] in P. aeruginosa,
reduce flagellin synthesis and expression [103, 104] and reduce production of bacterial
exoenzymes [100]. In murine models and in in vitro studies macrolides have shown to
Oncogenesis, Inflammatory and Parasitic Tropical Diseases of the Lung86
influence respiratory viral infections. In one study therapy with erythromycin increased
survival rates in mice infected with lethal doses of influenza virus [110]. This effect might be
exerted through the inhibitory action of erythromycin against virus-induced inflammatory
responses in the lung. The production of interferon-gamma (IFN-γ) in the lungs was signifi‐
cantly decreased by the administration of erythromycin to the infected mice. Two in vitro
studies researching the effect of erythromycin and clarithromycin in human tracheal cells
infected with rhinovirus and influenza A virus, also showed that macrolides decrease the
production of pro-inflammatory cytokines and inhibited activation of nuclear factor-κB (a
regulating factor in transcription of DNA in response to cellular stress) [111, 112]. These
antiviral effects of macrolides have not yet been proven in patients, although there is evidence
that macrolides may prevent common colds which are mostly of viral aetiology [113]. Macro‐
lides support the airway innate immune system by maintaining airway epithelial integrity
[114, 115]. In vitro [116] and in vivo [117] studies show that macrolides improve alveolar
macrophage phagocytosis function. Macrolide therapy stimulates the prolonged degranula‐
tion of neutrophils (suggesting anti-inflammatory activity in non-infective inflammation),
decreases long term oxidative burst and can decrease the release of pro-inflammatory cyto‐
kines (such as IL-6 and IL-8) in healthy individuals [118]. In vitro it is observed that macrolides
decrease the release of IL-1β, IL-6 and tumor necrosis factor-alpha (TNF-α) in sputum cells of
patients with COPD [119]. Azithromycin exerts direct inhibitory effects on mucus secretion
from airway epithelial cells in vitro and in vivo [120].
7.5.2. Success of macrolides in chronic lung diseases
Diffuse panbronchiolitis is a progressive inflammatory disorder of the airways found almost
exclusively in Japan. Clinically it is characterized by chronic cough, excessive sputum pro‐
duction, exertional breathlessness, chronic sinusitis and Pseudomonas colonization [121].
Untreated, the prognosis of diffuse panbronchiolitis is poor, with progressive deterioration of
lung function, the development of diffuse bronchiectasis and death caused by respiratory
failure. The introduction of long-term macrolide therapy has resulted in dramatic improve‐
ments in survival, with 5-year survival rates increasing from 63 to 92% [121, 122]. Significant
symptom reduction and improved pulmonary function have also been achieved [123-126].
Also in patients with cystic fibrosis (CF) who are colonized with P. aeruginosa, macrolide
therapy had led to improvement in FEV1 and forced vital capacity (FVC), a reduction in
exacerbation rate, a reduction in hospital days and days of intravenous antibiotic use, delaying
time until the first exacerbation and reducing number of additional courses of antibiotics
[127-132]. A Cochrane review of macrolide therapy concluded that treatment with azithro‐
mycin had a small but significant effect on pulmonary function in patients with cystic fibrosis
[133]. In a in New Zealand performed randomized controlled trial in non-CF bronchiectasis,
maintenance treatment with 3 times a week 500 mg azithromycin showed a reduction in
exacerbations [134] though no effects were seen in quality of life and lung function. In a Dutch
study where a treatment scheme was given with daily 250 mg azithromycin, the reduction in
exacerbations was accompanied by an improved quality of life assessed by St George’s
Respiratory Questionnaire (SGRQ) and an increase in lung function [135]. As for COPD there
have been few researches concerning macrolides in preventing AECOPD. One published study
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has examined the effect of clarithromycin treatment in COPD [136]. This was a prospective
double-blind randomized controlled trial of 67 patients with moderately severe COPD. The
effects of 3 months’ clarithromycin therapy on health status, exacerbation rate and sputum
bacterial numbers were measured. Overall, no significant benefit was seen in any measure.
However, significant improvements in both the SGRQ symptom score and 36-item short-form
health survey (SF-36) physical function score were seen. A Japanese study performed in 1997
investigated the effect of long-term erythromycin therapy on common colds in patients with
COPD [113]. It was a prospective, randomized, controlled but not blinded study. Patients who
received erythromycin therapy had less common colds and less subsequent AECOPD
compared to patients in the control group. In 2006, another study had been performed in the
UK to investigate the influence of erythromycin on exacerbation of COPD [137]. Unfortunately,
the total number of patients needed for inclusion was not reached. Although the study showed
a significant reduction in number of exacerbations in COPD patients who received 1 year daily
erythromycin, the reached conclusions should be carefully interpreted. The most recent study
published concerning long term macrolide therapy in COPD was performed in the USA with
over 1,000 patients. It showed a reduction in time to first exacerbation and a reduced risk for
exacerbations in patients receiving daily azithromycin during 1 year [138]. The study partici‐
pants were patients who had at least 1 treated exacerbation in the previous year or who were
on continuous supplemental oxygen or had an emergency department (ED) visit or hospital
admission for an exacerbation COPD. The applicability of these results is somewhat difficult.
The results of the study could suggest that long term azithromycin can be given to many COPD
patients, even to those who are not actually frequent exacerbators. The place of azithromycin
in the prevention of COPD exacerbations is a topic which needs further research.
7.5.3. Antimicrobial resistance
Giving long term antibiotic treatment to a patient may have consequences; the development
of antimicrobial resistance is by far the most important one. Several researches have shown
that the erm(B) and mef genes are mostly responsible for macrolide resistance in streptococci
bacteria [139-142]. This resistance can develop even when short term therapy with macrolides
is given [141]. The participants receiving azithromycin in the USA study, where a 1-year
therapy was administered, were less likely to be colonized with respiratory pathogens but
more likely to become colonized with macrolide resistant pathogens [138]. In the UK study in
patients with COPD the researchers found there were no significant changes in resistance of
sputum pathogens (H. influenzae, S. pneumoniae, M. catarrhalis) after 1 year of daily erythro‐
mycin [137]. In a Dutch study investigating antibiotic treatment before cardiovascular surgery
300 patients were treated with 2 weeks of clarithromycin. A significant rise in macrolide
resistance in oropharyngeal flora was observed and this resistance continued to exist for at
least 8 weeks [140]. Since macrolide resistance in pneumococci is already a known problem
[141, 143, 144] it is of great importance to prevent the development of resistance in other
microorganisms.
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